title: [Clinical and immunological improvement of myasthenia gravis following treatment with denosumab].
authors.affiliation: Complexo Hospitalario de Ourense, Ourense, Espana.
authors.forename: D
authors.initials: D
authors.lastname: Rodriguez-Gomez
authors.affiliation: Complexo Hospitalario de Ourense, Ourense, Espana.
authors.forename: A
authors.initials: A
authors.lastname: Gonzalez-Noya
authors.affiliation: Complexo Hospitalario de Ourense, Ourense, Espana.
authors.forename: J
authors.initials: J
authors.lastname: Marnotes-Gonzalez
authors.affiliation: Complexo Hospitalario de Ourense, Ourense, Espana.
authors.forename: A M
authors.initials: AM
authors.lastname: Lorenzo-Vizcaya
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood; D001324:Autoantigens / Q000276:immunology; D000069448:Denosumab / Q000627:therapeutic use*; D005260:Female; D005598:Fractures, Spontaneous / Q000139:chemically induced; D006801:Humans; D009157:Myasthenia Gravis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D011950:Receptors, Cholinergic / Q000276:immunology; D012074:Remission Induction
chemical_list: D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D001324:Autoantigens; D053245:RANK Ligand; D011950:Receptors, Cholinergic; C505688:TNFSF11 protein, human; D000069448:Denosumab; D011729:Pyridostigmine Bromide